Nunc vials

Manufactured by Thermo Fisher Scientific

Nunc vials are high-quality laboratory storage containers designed for a variety of applications. They are made of durable materials and come in different sizes and configurations to meet the needs of various research and testing requirements.

Automatically generated - may contain errors

Lab products found in correlation

Phoenix winnonlin version 7, by Certara (1 mentions)

Spelling variants of this product

NuncTM (46 citations) Nunc™ CryoTube™ Vials (6 citations) Nunc Cryotubes Vials (2 citations)

4 protocols using nunc vials

Lung Cancer Tissue Collection and Annotation

Check if the same lab product or an alternative is used in the 5 most similar protocols

De-identified malignant and adjacent non-malignant (control) lung tissues were harvested in the operating room from patients having resection for NSCLC, none of whom received preoperative treatment. The matching control lung tissue was always taken from areas 8–10 cm removed from the cancer bed. Two to three tissue pieces were aliquoted into 1.5 ml Nunc vials in the operating room after resection of the cancer, and frozen in liquid nitrogen within 30 s. Each vial was barcoded, and stored at −80°C. Specimens were annotated for diagnosis (including stage), age, gender, race, histology and smoking status (pack-years). For this study, the following criteria was used: (a) current or former smokers, (b) adenocarcinoma histology, (c) pathological stage IA or IB and (d) signed the IRB consent form.

Fahrmann J.F., Grapov D., Wanichthanarak K., DeFelice B.C., Salemi M.R., Rom W.N., Gandara D.R., Phinney B.S., Fiehn O., Pass H, & Miyamoto S. (2017). Integrated metabolomics and proteomics highlight altered nicotinamide and polyamine pathways in lung adenocarcinoma. Carcinogenesis, 38(3), 271-280.

+ Open protocol

+ Expand

Profiling Lung Cancer Tissue Samples

Check if the same lab product or an alternative is used in the 5 most similar protocols

De-identified malignant and adjacent non-malignant lung tissue was obtained from the New York University biorespository. Residual tumor and adjacent non-malignant tissue was harvested from the resected lung after routine pathological protocols were completed, following an approved IRB protocol with patient consent. Two to three tissue pieces were aliquoted into 1.5 ml Nunc vials, and then immediately placed in liquid nitrogen. After transport in liquid nitrogen, each vial was barcoded, and stored at −80°C until analyzed. All specimens were clinically annotated for age, gender, race, histology, smoking status, pack-years and stage of disease. For this clinical study, samples were selected that came from patients who met the following criteria: a) current or former smokers, b) adenocarcinoma histology, c) pathological stage IA or IB, and d) had understood and signed the IRB consent form.

Wikoff W.R., Grapov D., Fahrmann J.F., DeFelice B., Rom W., Pass H., Kim K., Nguyen U., Taylor S.L., Kelly K., Fiehn O, & Miyamoto S. (2015). Metabolomic Markers of Altered Nucleotide Metabolism in Early Stage Adenocarcinoma. Cancer prevention research (Philadelphia, Pa.), 8(5), 410-418.

+ Open protocol

+ Expand

Pharmacokinetics of Sublingual Fentanyl

Check if the same lab product or an alternative is used in the 5 most similar protocols

Pharmacokinetic (PK) samples were taken pre-dosing, and at 10, 20, 30, 40, 50, 60, 90, 180, and 360 min after administration of sublingual fentanyl.
Blood samples (4.5 mL) were collected in potassium ethylenediaminetetraacetic acid (EDTA) coated tubes and centrifuged for 10 min at 2500 to 3000× g at 4 °C. Plasma was transferred into polypropylene tubes (1.8 mL Nunc vials), which was stored at T < −70 °C (T < −20 °C during collection period) until the time of analysis. Fentanyl in plasma was quantitated using a validated UPLC-MS/MS method [33 (link)].
Pharmacokinetic data were analyzed by using Phoenix WinNonlin version 7.0 (Certara, Princeton, NJ, USA) to analyze concentration-versus-time data. Peak concentration (C_max), time to peak concentration (T_max), and area under the concentration-time curve (AUC) from 0 to 6 h after administration, were calculated.

Kuip E.J., Oldenmenger W.H., Oomen-de Hoop E., Verduijn G.M., Thijs-Visser M.F., de Bruijn P., van Meerten E., Koolen S.L., Mathijssen R.H, & van der Rijt C.C. (2018). Pharmacokinetics of Sublingually Delivered Fentanyl in Head and Neck Cancer Patients Treated with Curatively Aimed Chemo or Bioradiotherapy. Cancers, 10(11), 445.

+ Open protocol

+ Expand

Evaluation of Inflammatory Markers in Aortic Surgery

Check if the same lab product or an alternative is used in the 5 most similar protocols

We chose to measure IL-6, IL-8, and CRP due to their validity in reflecting the level of acute-phase response in major aortic surgery.20 (link),25 (link) The time points were chosen to capture fluctuation over time. IL-6 and IL-8 usually peak during the first 24 hours postoperatively, but CRP peaks at a later time.10 (link),25 (link),26 (link) Blood samples were taken at the following six different time points:

Before surgery

After completion of distal anastomosis and flow to one of the lower limbs was reestablished

Six hours after beginning of surgery

Twelve hours after beginning of surgery

Twenty-four hours after beginning of surgery

At discharge from hospital.

Blood samples were primarily taken from arterial catheter, or if not possible, from central venous catheter or peripheral vein. Samples were centrifuged at 4°C, 1106 g within 1 hour from sampling. Two milliliters of serum sample was frozen in plastic Nunc vials, within 2 hours from sampling, at −80°C until further analysis.

Krog A.H., Sahba M., Pettersen E.M., Sandven I., Thorsby P.M., Jørgensen J.J., Sundhagen J.O, & Kazmi S.S. (2016). Comparison of the acute-phase response after laparoscopic versus open aortobifemoral bypass surgery: a substudy of a randomized controlled trial. Vascular Health and Risk Management, 12, 371-378.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!